Merck & Co Inc (LSE:0QAH)
$ 100 0 (0%) Market Cap: 252.20 Bil Enterprise Value: 275.80 Bil PE Ratio: 20.90 PB Ratio: 5.67 GF Score: 87/100

Merck & Co Inc at Evercore HealthCONx Conference Transcript

Dec 04, 2019 / 07:00PM GMT
Release Date Price: $84.12
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Okay. Well, thank you all for being here. Pleasure to have Merck management join us. Mike, pleasure to have you. Peter, pleasure to have you guys join. Before we get going, perhaps turning it over to you guys just to kick things off, what's on top of your minds, the biggest priorities, and we'll jump right into it.

Questions & Answers

Michael T. Nally
Merck & Co., Inc. - CMO & Executive VP

Great. Yes. Well, thank you very much, Umer. Thanks to the team for having us today. 2019 has been a good year for us, right? I think we have the business performing well on multiple fronts. Clearly, we continue to experience success with our oncology portfolio, led by KEYTRUDA, which the momentum continues to grow strong.

We've obviously seen a huge opportunity. We've been able to capitalize on the huge opportunity among cancer where in the United States today, about 8 out of every 10 patients in this indication are now

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot